Barnard-Brak Lucy, Davis Tonya N, Schmidt Marcelo, Richman David M
a College of Education, Texas Tech University , Lubbock , Texas , USA .
b Department of Educational Psychology , School of Education, Baylor University , Waco , Texas , USA , and.
Dev Neurorehabil. 2016;19(1):46-53. doi: 10.3109/17518423.2014.904949. Epub 2014 Apr 16.
Families of children with autism spectrum disorder are barraged by different treatment options. Some of these options have the support of empirical evidence while others do not. Stimulant treatments are typically utilized to treat symptoms of ADHD indicating an on-label use of such treatment.
This study examines the association of stimulant treatment with the on- (symptoms of ADHD) and off- (symptoms of ASD) label symptoms among children with ASD via a non-clinical, population-based sample.
Results indicate no significant association of stimulant treatment with a reduction of on- or off-label symptoms among children with ASD.
Stimulant medications utilized in the treatment of DSM core symptoms of autism spectrum disorder would be considered an off-label use because there is limited evidence to support that stimulants are effective in treating core symptoms of ASD, which is supported by the results of the current study.
患有自闭症谱系障碍的儿童家庭面临着各种各样的治疗选择。其中一些选择有实证依据的支持，而另一些则没有。兴奋剂治疗通常用于治疗多动症症状，表明这种治疗是按标签使用。
本研究通过一个非临床的、基于人群的样本，考察了兴奋剂治疗与自闭症谱系障碍儿童的标签上（多动症症状）和标签外（自闭症谱系障碍症状）症状之间的关联。
结果表明，兴奋剂治疗与自闭症谱系障碍儿童标签上或标签外症状的减轻之间没有显著关联。
用于治疗自闭症谱系障碍DSM核心症状的兴奋剂药物将被视为标签外使用，因为目前有限的证据支持兴奋剂在治疗自闭症谱系障碍核心症状方面是有效的，本研究结果也证实了这一点。
